Skip to Main Content

Paper Details

Targeting ferroptosis: A novel therapeutic strategy for the treatment of mitochondrial disease-related epilepsy.
PLoS One
50
2019
-tocotrienol quinone, 15, 15-HETE, 15-LO, 15-hydroxyeicosatetraenoic acid, 15-lipoxygenase, B-lymphocytes, EPI-743, Epilepsy, Ferroptosis, GPX4, Mitochondrial disease, PCH6, Primary fibroblasts, RSL3, children, epilepsy, ferroptosis, genetic disorders, glutathione, glutathione peroxidase-4, iron, lipoxygenase enzymes, mitochondrial disease, mitochondrial disease-associated epilepsies, mitochondrial diseases, mitochondrial disorder, patient, patient cells, patients, pediatric disease, pontocerebellar hypoplasia type 6, vatiquinone
Author NameAffiliation
Euan A AshleyStanford Center for Undiagnosed Diseases, Stanford University School of Medicine
Matthew T WheelerStanford Center for Undiagnosed Diseases, Stanford University School of Medicine
Matthew T WheelerStanford Center for Undiagnosed Diseases, Stanford University School of Medicine
Enrico BertiniBambino Gesu Children's Research Hospital
Enrico BertiniBambino Gesu Children's Research Hospital
Gregory M EnnsStanford University School of Medicine
William A GahlNational Human Genome Research Institute (NHGRI), National Institutes of Health
William A GahlNational Human Genome Research Institute (NHGRI), National Institutes of Health
Lynne A WolfeNational Human Genome Research Institute (NHGRI), National Institutes of Health
Lynne A WolfeNational Human Genome Research Institute (NHGRI), National Institutes of Health
Russell P SanetoNeuroscience Institute, Seattle Children's Hospital
Jeff K TrimmerBioElectron Technology Corporation
  • 1 - 12

Datasets

Release 1.2